Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2019
October 25, 2019 at 04:55 am EDT
Share
Wuhan Hiteck Biological Pharma Co.,Ltd announced earnings results for the nine months ended September 30, 2019. For the nine months, the company announced sales was CNY 470.523 million compared to CNY 412.051 million a year ago. Operating income was CNY 83.780 million compared to CNY 85.644 million a year ago. Net income was CNY 68.128 million compared to CNY 75.985 million a year ago. Basic earnings per share from continuing operations was CNY 0.66 compared to CNY 0.74 a year ago.
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.
WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD 
